Market: NMS |
Currency: USD
Address: 55 Cambridge Parkway
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Show more
📈 KalVista Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$34.33
-
Upside/Downside from Analyst Target:
114.32%
-
Broker Call:
18
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-05-05
-
EPS Estimate:
-0.38
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for KalVista Pharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2026-05-05 (estimated upcoming) | - |
| 2025-12-11 | - |
| 2025-11-10 | -0.92 |
| 2025-09-11 | -1.12 |
| 2025-07-10 | -0.99 |
| 2024-12-04 | -0.91 |
| 2024-09-05 | -0.87 |
| 2024-07-11 | -1.07 |
| 2024-03-11 | -0.84 |
| 2023-12-07 | -0.8 |
| 2023-09-07 | -0.74 |
| 2023-07-06 | -0.77 |
| 2023-03-09 | -0.75 |
| 2022-12-08 | -0.9 |
| 2022-09-08 | -0.94 |
| 2022-07-07 | -0.98 |
| 2022-03-10 | -0.92 |
| 2021-12-09 | -0.8 |
| 2021-09-09 | -0.66 |
| 2021-07-13 | -0.67 |
| 2021-03-11 | -0.56 |
| 2020-12-10 | -0.58 |
| 2020-09-14 | -0.61 |
| 2020-06-28 | -0.37 |
| 2020-03-10 | -0.52 |
📰 Related News & Research
🔍 View more Reports
